ISSN: ISSN: 2157-7412
Department of Biochemistry and Molecular Biology
University of Nebraska Medical Center, USA
Dr Murielle Mimeault, M.Sc, Ph.D., has over 16 years of the experience in molecular pharmacology, cellular biology, cancer biology and targeted therapy. She has contributed to numerous scientific articles on the validation of novel biomarkers and combination therapies targeting key gene products including EGFR, hedgehog and macrophage inhibitory cytokine-1 that are overexpressed in cancer cells during disease progression and metastases. She is currently working at the Department of Biochemistry and Molecular Biology in the College of Medicine at the University of Nebraska Medical Center on the validation of novel biomarkers and therapeutic targets in cancer stem/progenitor cells and their progenies for improving the efficacy of current clinical treatments against aggressive, metastatic and lethal cancers, including castration-resistant prostate cancer and pancreatic cancer.
Dr Murielle Mimeault\'s recent research interests focus on metabolic pathways altered in cancer cells under normoxic and hypoxic conditions.